Anti-POT1, Polyclonal [MTA40]
Invented at Cancer Research UK London Research Institute: Clare Hall Laboratories
- Datasheet
- References (4)
- Inventor Info
Info
![Western blot using Anti-POT1, Polyclonal [MTA40] with siRNA KD of GFP (irrelevant RNA) and POT1.](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,q_auto/485aae8b-0fba-4770-8f67-fa129905a0ea.jpg)
![Western blot using Anti-POT1, Polyclonal [MTA40] with siRNA KD of GFP (irrelevant RNA) and POT1.](https://res.cloudinary.com/ximbio/image/upload/c_limit,fl_lossy,h_282,q_auto,w_368/485aae8b-0fba-4770-8f67-fa129905a0ea.jpg)
![Image thumbnail for Anti-POT1, Polyclonal [MTA40]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/485aae8b-0fba-4770-8f67-fa129905a0ea.jpg)
| Catalogue Number | 151570 |
| Applications | IP WB |
| Antigen/Gene or Protein Targets | POT1 |
| Reactivity | Human and Mouse |
| Relevance | POT1 (protection of telomeres 1) is part of the telomerase ribonucleotide (RNP) complex, which stabilises chromosomes by controlling telomere elongation. POT1 is a component of the double-stranded telomeric DNA-binding TRF1 complex which cis-inhibits telomerase. POT1 localization on telomeres diminishes in the absence of single-stranded DNA. |
| Host | Rabbit |
| Immunogen | Full-length human POT1 protein |
| Concentration | 1.5 mg/ml |
| Formulation | PBS, 0.1% NaN3 |
| Molecular Weight (kDa) | 70 |
| Notes |
Available as immunogen affinity purified. Recommended immunostaining protocol: Samples (50-100 μg) are separated by SDS-PAGE on 10% Bis-Tris gels for 1 to 1.5 hours at 180V and then transferred onto nitrocellulose membrane at 30V for 100 minutes. Blocking is performed for a minimum of 30 minutes in 5% milk in PBS-Tween and the MTA40 antibody is left for overnight incubation. The membrane is then washed in PBS-Tween and the secondary antibody (Third party manufacturer) is added for a minimum of one hour. After washing in PBS-Tween, the immunostaining is visualised with ECL reaction. |
| Positive Control | U2OS cells |
| Research Area | Cancer, Epigenetics & Nuclear Signalling |
References: 4 entries
Martinez et al. 2010. Nat Cell Biol. 12(8):768-80. PMID: 20622869.
Mammalian Rap1 controls telomere function and gene expression through binding to telomeric and extratelomeric sites.
Europe PMC ID: 20622869
Martínez et al. 2009. Genes Dev. 23(17):2060-75. PMID: 19679647.
Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice.
Europe PMC ID: 19679647
Add a reference
References: 4 entries
Martinez et al. 2010. Nat Cell Biol. 12(8):768-80. PMID: 20622869.
Mammalian Rap1 controls telomere function and gene expression through binding to telomeric and extratelomeric sites.
Martínez et al. 2009. Genes Dev. 23(17):2060-75. PMID: 19679647.
Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice.
Add a reference
